自主研发-话题@MedSci

#自主研发#

47篇内容 | 839人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1672196, encodeId=706616e2196d2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, objectType=article, longId=735859, objectId=3eebe358592e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eebe358592e, replyNumber=0, likeNumber=45, createdTime=2023-01-28, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eebe358592e, moduleTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eebe358592e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672194, encodeId=08f516e219404, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=冰洲石生物自主研发的创新雌激素受体嵌合降解剂AC0682临床申请获国家药监局批准, objectType=article, longId=723698, objectId=a233e2369829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a233e2369829, replyNumber=0, likeNumber=47, createdTime=2022-11-17, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a233e2369829, moduleTitle=冰洲石生物自主研发的创新雌激素受体嵌合降解剂AC0682临床申请获国家药监局批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a233e2369829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672193, encodeId=694b16e2193e9, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, objectType=article, longId=300977, objectId=fd013009e7ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd013009e7ec, replyNumber=0, likeNumber=44, createdTime=2022-07-02, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd013009e7ec, moduleTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd013009e7ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672195, encodeId=b49416e2195dd, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展, objectType=article, longId=726406, objectId=7befe264069b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7befe264069b, replyNumber=0, likeNumber=42, createdTime=2022-10-07, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7befe264069b, moduleTitle=物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7befe264069b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672192, encodeId=e6e016e2192a8, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=34, createdTime=2022-03-15, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672190, encodeId=547d16e2190de, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=赛诺联合医疗：自主研发核心器件，助力国产PET/CT 突破“卡脖子”瓶颈, objectType=article, longId=205325, objectId=620120532503, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=620120532503, replyNumber=0, likeNumber=50, createdTime=2021-07-28, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=620120532503, moduleTitle=赛诺联合医疗：自主研发核心器件，助力国产PET/CT 突破“卡脖子”瓶颈, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=620120532503)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672191, encodeId=f77916e219163, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=我国第二个自主研发的mRNA新冠疫苗产品获批临床, objectType=article, longId=205475, objectId=19ec2054e53f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ec2054e53f, replyNumber=0, likeNumber=39, createdTime=2021-07-08, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ec2054e53f, moduleTitle=我国第二个自主研发的mRNA新冠疫苗产品获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ec2054e53f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672186, encodeId=451f16e2186ab, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=打破国外垄断中国自主研发的心血管OCT系统有何“绝活”？, objectType=article, longId=197915, objectId=66b419e91521, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b419e91521, replyNumber=0, likeNumber=26, createdTime=2020-08-30, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b419e91521, moduleTitle=打破国外垄断中国自主研发的心血管OCT系统有何“绝活”？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b419e91521)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672184, encodeId=7dba16e21840d, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=即刻起效，仅需超声引导！葛均波院士等报告自主研发ValveClamp治疗二尖瓣反流经验, objectType=article, longId=195552, objectId=b40f1955523a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40f1955523a, replyNumber=0, likeNumber=32, createdTime=2021-02-25, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40f1955523a, moduleTitle=即刻起效，仅需超声引导！葛均波院士等报告自主研发ValveClamp治疗二尖瓣反流经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40f1955523a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672188, encodeId=a5f916e2188a4, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, objectType=article, longId=204978, objectId=edf02049e8ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf02049e8ca, replyNumber=0, likeNumber=34, createdTime=2021-05-15, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf02049e8ca, moduleTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf02049e8ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672187, encodeId=11da16e2187c6, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=中国自主研发抗高脂血症化学1类新药DC371739进入临床试验, objectType=article, longId=199837, objectId=680b19983e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680b19983e13, replyNumber=0, likeNumber=44, createdTime=2021-02-11, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680b19983e13, moduleTitle=中国自主研发抗高脂血症化学1类新药DC371739进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=680b19983e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672189, encodeId=566716e21897f, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=我国自主研发“三层仿生”人工血管完成首例腹主动脉置换术, objectType=article, longId=205247, objectId=d32d20524eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d32d20524eb6, replyNumber=0, likeNumber=41, createdTime=2021-12-02, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d32d20524eb6, moduleTitle=我国自主研发“三层仿生”人工血管完成首例腹主动脉置换术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d32d20524eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672181, encodeId=d33316e218153, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=全球第二款！中国自主研发13价肺炎结合疫苗获批上市, objectType=article, longId=185541, objectId=cfc7185541fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc7185541fc, replyNumber=0, likeNumber=37, createdTime=2020-11-16, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc7185541fc, moduleTitle=全球第二款！中国自主研发13价肺炎结合疫苗获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc7185541fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672182, encodeId=e01f16e218287, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=首批自主研发的新冠病毒抗体化学发光法检测试剂盒获准上市, objectType=article, longId=189471, objectId=1d791894e1b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d791894e1b4, replyNumber=0, likeNumber=28, createdTime=2021-01-12, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d791894e1b4, moduleTitle=首批自主研发的新冠病毒抗体化学发光法检测试剂盒获准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d791894e1b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672183, encodeId=9b2816e218312, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=自主研发数字PCR系统，「达普生物」获千万元天使轮融资, objectType=article, longId=190958, objectId=b78919095886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b78919095886, replyNumber=0, likeNumber=32, createdTime=2020-12-06, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b78919095886, moduleTitle=自主研发数字PCR系统，「达普生物」获千万元天使轮融资, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78919095886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672180, encodeId=0b7116e218076, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, objectType=article, longId=184677, objectId=6ed31846e733, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed31846e733, replyNumber=0, likeNumber=41, createdTime=2020-06-01, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed31846e733, moduleTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed31846e733)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672177, encodeId=8de016e2177cd, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”, objectType=article, longId=181179, objectId=d68a1811e971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68a1811e971, replyNumber=0, likeNumber=40, createdTime=2019-11-24, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68a1811e971, moduleTitle=2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68a1811e971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672179, encodeId=da4016e2179a2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, objectType=article, longId=183487, objectId=cbd518348e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbd518348e01, replyNumber=0, likeNumber=49, createdTime=2020-10-15, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbd518348e01, moduleTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbd518348e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672178, encodeId=f91416e21788c, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”, objectType=article, longId=181293, objectId=b6141812936b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6141812936b, replyNumber=0, likeNumber=38, createdTime=2020-05-05, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6141812936b, moduleTitle=2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6141812936b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1672185, encodeId=592516e218573, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, objectTitle=医科院生物所自主研发的新冠病毒灭活疫苗进入Ⅱ期临床试验, objectType=article, longId=196247, objectId=cd0319624e98, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd0319624e98, replyNumber=0, likeNumber=50, createdTime=2021-01-26, rootId=0, userName=xlwang2700, userId=6d2c26890289, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd0319624e98, moduleTitle=医科院生物所自主研发的新冠病毒灭活疫苗进入Ⅱ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd0319624e98)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

自主研发

2020-05-29

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕

2023-01-28

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

冰洲石生物自主研发的创新雌激素受体嵌合降解剂AC0682临床申请获国家药监局批准

2022-11-17

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

我国自主研发的抗新冠口服药 VV116 启动三期临床研究

2022-07-02

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

物传人的概率为空气传播的千分之一，我国自主研发的mRNA疫苗获批临床试验丨新冠研究一周进展

2022-10-07

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2022-03-15

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

赛诺联合医疗：自主研发核心器件，助力国产PET/CT 突破“卡脖子”瓶颈

2021-07-28

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

我国第二个自主研发的mRNA新冠疫苗产品获批临床

2021-07-08

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

打破国外垄断中国自主研发的心血管OCT系统有何“绝活”？

2020-08-30

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

即刻起效，仅需超声引导！葛均波院士等报告自主研发ValveClamp治疗二尖瓣反流经验

2021-02-25

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录

2021-05-15

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

中国自主研发抗高脂血症化学1类新药DC371739进入临床试验

2021-02-11

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

我国自主研发“三层仿生”人工血管完成首例腹主动脉置换术

2021-12-02

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

全球第二款！中国自主研发13价肺炎结合疫苗获批上市

2020-11-16

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

首批自主研发的新冠病毒抗体化学发光法检测试剂盒获准上市

2021-01-12

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

自主研发数字PCR系统，「达普生物」获千万元天使轮融资

2020-12-06

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定

2020-06-01

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”

2019-11-24

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物

2020-10-15

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

2019 CSCO 大咖发声：国内自主研发抗肿瘤药物研发“全面开花”

2020-05-05

xlwang2700 (审核中...)

前往app查看评论内容

#自主研发#

医科院生物所自主研发的新冠病毒灭活疫苗进入Ⅱ期临床试验

2021-01-26

科室
- - 订阅+
  - 更多科室
工具
服务